Tuesday, October 4, 2022


Biotechnology News Magazine

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced that in an independent validation study, PrismRA accurately predicted which patients with rheumatoid arthritis would not achieve EULAR good response criteria at six months of treatment using either adalimumab or etanercept.

A validation study with 68 RA patients who started either adalimumab or etanercept as their first biologic was recently presented at EULAR on June 2, 2021, along with the Sint Maartenskliniek in the Netherlands.  The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.

The study found a EULAR-based inadequate response in 37 out of the 68 patients, or 54.4%. The study demonstrated that patients with a molecular signature of non-response were four times more likely to achieve a EULAR inadequate response at six months than those lacking the molecular signature. Identifying those patients who will not respond to TNFi therapy in advance, before treatment begins, has the potential to reduce time spent on trial-and-error approaches and could result in improved outcomes and decreased patient burden.

“The successful validation of the novel test for EULAR inadequate response in this treat-to-target setting is promising,” said Johanna Withers, Ph.D., study co-author, and Principal Scientist at Scipher Medicine. “This could optimize care, reducing wasted time on ineffective therapies and potentially halting disease progression. Demonstrating PrismRA’s ability to accurately predict non-response in an independent cohort outside of the United States further demonstrates the tests generalizability across diverse patient populations.”

In addition to this collaboration with the Sint Maartenskliniek, Scipher Medicine also published new data on the ability of PrismRA to predict inadequate response to TNF inhibitor therapies in seronegative RA patients as well as on efforts to define high-confidence treatment response outcomes using a Monte Carlo simulation approach to evaluate the true impact of therapeutic efficacy and response.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine